Date: 2016-09-20
Type of information: Establishment of a new subsidiary in the EU
Compound:
Company: Alnylam Therapeutics (USA - MA)
Therapeutic area: Rare diseases - Genetic diseases
Type agreement: establishment of a new subsidiary in the EU
Action mechanism:
Disease:
Details: * On September 20, 2016, Alnylam Pharmaceuticals announced the expansion of its global footprint with the opening of a new development and commercial hub in Maidenhead, UK . In anticipation of substantial growth across Alnylam over the next five years, the office opens with a core Clinical Development, Regulatory Affairs, and Commercial team and space for an additional 100 employees. An office in Maidenhead allows Alnylam to support company growth in Europe , through its access to highly-skilled individuals, and proximity to scientific centres and regulatory agencies. Alnylam's progress with its clinical programmes in the UK to date has been in large part due to the support and contributions of numerous expert collaborators at many outstanding Phase 1 units and academic sites across the UK .
Financial terms:
Latest news:
